小青龙汤加减联合沙美特罗替卡松粉吸入剂治疗支气管哮喘患者的效果OA
Effect of Modified Xiaoqinglong Decoction Combined with Salmeterol Ticasone Powder Inhalant in the Treatment of Patients with Bronchial Asthma
目的:观察小青龙汤加减联合沙美特罗替卡松粉吸入剂治疗支气管哮喘患者的效果.方法:选取 2022 年 1 月—2023 年 6 月永泰县中医院收治的 158 例支气管哮喘患者作为研究对象,根据抛硬币法将其分为西药组和试验组,各 79 例.西药组给予沙美特罗替卡松粉吸入剂,试验组在西药组基础上给予小青龙汤加减治疗.比较两组临床疗效,治疗前、治疗2周后呼吸情况、肺功能,不良反应及复发情况.结果:试验组总有效率高于西药组,差异有统计学意义(P<0.05).治疗 2 周后,两组肺部症状、活动能力、生活质量评分均降低,试验组肺部症状、活动能力、生活质量评分均低于西药组,差异有统计学意义(P<0.05).治疗 2 周后,两组呼气峰值流速(PEF)、用力肺活量(FVC)、最大呼气中期流速(MMF)、第 1 秒用力呼气容积(FEV1)均升高,试验组PEF、FVC、MMF、FEV1 均高于西药组,差异有统计学意义(P<0.05).治疗 2 周后,两组转化生长因子-β1(TGF-β1)、神经生长因子(NGF)、血栓素B2(TXB2)水平均降低,γ干扰素(IFN-γ)水平升高,试验组TGF-β1、NGF、TXB2 水平均低于西药组,IFN-γ水平高于西药组,差异有统计学意义(P<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05).随访 6 个月后,试验组复发率低于西药组,差异有统计学意义(P<0.05).结论:支气管哮喘患者应用小青龙汤加减与沙美特罗替卡松粉吸入剂联合治疗效果显著,明显改善患者呼吸健康受损情况和肺功能、细胞因子水平,降低复发率,且安全性较好.
Objective:To observe the effect of modified Xiaoqinglong Decoction combined with Salmeterol Ticasone Powder Inhalant in the treatment of patients with bronchial asthma.Method:A total of 158 patients with bronchial asthma who admitted to Yongtai County Hospital of Traditional Chinese Medicine from January 2022 to June 2023 were selected as the study objects,they were divided into the western medicine group and the experimental group,79 cases in each group.The western medicine group was given Salmeterol Ticasone Powder Inhalant,and the experimental group was given modified Xiaoqinglong Decoction based on the western medicine group.The clinical efficacy,respiratory status,lung function before treatment and after 2 weeks of treatment,adverse reactions and recurrence were compared between two groups.Result:The total effective rate of the experimental group was higher than that of the western medicine group,and the difference was statistically significant(P<0.05).After 2 weeks of treatment,the pulmonary symptoms,activity ability and quality of life scores of two groups were decreased,and the pulmonary symptoms,activity ability and quality of life scores of the experimental group were lower than those of the western medicine group,the differences were statistically significant(P<0.05).After 2 weeks of treatment,the peak expiratory flow rate(PEF),forced vital capacity(FVC),maximum mid-expiratory flow rate(MMF)and forced expiratory volume in one second(FEV1)of two groups were increased,and the PEF,FVC,MMF and FEV1 of the experimental groups were all higher than those of the western medicine group,the differences were statistically significant(P<0.05).After 2 weeks of treatment,the levels of transforming growth faction-β1(TGF-β1),nerve growth factor(NGF)and thromboxane B2(TXB2)in two groups were decreased,and the levels of interferon-γ(IFN-γ)were increased,the levels of TGF-β1,NGF and TXB2 in the experimental groups were lower than those in the western medicine group,and the level of IFN-γ was higher than that in the western medicine group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).After 6 months of follow-up,the recurrence rate of the experimental group was lower than that of the western medicine group,and the difference was statistically significant(P<0.05).Conclusion:Modified Xiaoqinglong Decoction combined with Salmeterol Ticasone Powder Inhalant has significant effect in patients with bronchial asthma,significantly improving respiratory health impairment condition,lung function and cytokine levels,and reducing recurrence rate,with good safety.
翁小霖
永泰县中医院 福建 永泰 350700
小青龙汤沙美特罗替卡松粉吸入剂支气管哮喘肺功能
Xiaoqinglong DecoctionSalmeterol Ticasone Powder InhalantBronchial asthmaLung function
《中外医学研究》 2024 (018)
15-19 / 5
评论